Trial Profile
A Phase I Trial of ONX-0801 (a Novel α-folate Receptor-mediated Thymidylate Synthase Inhibitor) Exploring Once Weekly and Alternate Week Dosing Regimens in Patients With Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Idetrexed (Primary) ; Dexamethasone
- Indications Endometrial cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man
- 19 Aug 2022 Results published in the Clinical Cancer Research
- 08 Mar 2021 Status changed from active, no longer recruiting to completed.
- 16 Nov 2020 Planned End Date changed from 1 Aug 2020 to 1 Aug 2021.